HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested an experimental drug called TransCon TLR7/8 Agonist, given as injections into tumors, for people with advanced solid tumors that had stopped responding to standard treatments. The drug was tested alone or with another immunotherapy (pembrolizumab). The main goal…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1, PHASE2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
Experimental radiation drug for advanced cancers halted early
Disease control TerminatedThis study tested a new drug that delivers radiation directly to cancer cells in people with advanced solid tumors (like breast, ovarian, or head and neck cancers) that had stopped responding to standard treatments. The goal was to find a safe dose and see if it could shrink tumo…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC